[
    [
        {
            "time": "2018-03-15",
            "original_text": "Steven Cohen's Point72 Piles Into Menlo Therapeutics",
            "features": {
                "keywords": [
                    "Steven Cohen",
                    "Point72",
                    "Menlo Therapeutics"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Steven Cohen's Point72 Piles Into Menlo Therapeutics",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-06-20",
            "original_text": "Durham is on a winning streak for new jobs, but will it continue?",
            "features": {
                "keywords": [
                    "Durham",
                    "winning streak",
                    "new jobs"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "economy"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Durham is on a winning streak for new jobs, but will it continue?",
                "Correlation": 2,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 2,
                "Duration": 3,
                "Entity_Density": 1,
                "Market_Scope": 2,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-04-10",
            "original_text": "Health stocks reverse coronavirus gains as one analyst says the market is overreacting",
            "features": {
                "keywords": [
                    "Health stocks",
                    "reverse",
                    "coronavirus",
                    "gains",
                    "overreacting"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Health stocks reverse coronavirus gains as one analyst says the market is overreacting",
                "Correlation": 6,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-02-12",
            "original_text": "Top Stock Analyst Reports for Pfizer, Wells Fargo & SAP",
            "features": {
                "keywords": [
                    "Stock Analyst Reports",
                    "Pfizer",
                    "Wells Fargo",
                    "SAP"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "finance",
                    "technology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Top Stock Analyst Reports for Pfizer, Wells Fargo & SAP",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2022-07-05",
            "original_text": "Glaxo's Multiple Myeloma Candidate Gets FDA's Priority Review",
            "features": {
                "keywords": [
                    "Glaxo",
                    "Multiple Myeloma",
                    "FDA",
                    "Priority Review"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Glaxo's Multiple Myeloma Candidate Gets FDA's Priority Review",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-01-25",
            "original_text": "Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?",
            "features": {
                "keywords": [
                    "First Trust",
                    "Capital Strength ETF",
                    "FTCS",
                    "Investing Radar"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]